Bayer will use Biomni Lab agents for drug research
Bayer has partnered with Phylo to gain full access to Biomni Lab, bringing scientific literature and omics evidence into one research environment.
AT A GLANCE
Key points
- Bayer scientists will receive full access to Biomni Lab.
- The first workflows will combine literature and omics evidence.
- The platform preserves sources, methods and execution steps for inspection.
- The announcement does not report a clinical result or drug approval.
What is changing?
Phylo announced on October 22 that it has partnered with Bayer to use Biomni Lab in drug research. Bayer scientists will gain full access to the agentic platform, which combines scientific literature, biomedical data and analytical methods in one workspace.
The initial use case will focus on assembling literature and omics evidence for drug discovery. Phylo says each workflow preserves its sources, methods and execution steps so scientists can inspect the results and apply their own scientific judgment.
The announcement does not report a new clinical outcome or drug approval. Biomni Lab’s practical impact will depend on the reproducibility of agent-generated analyses, integration with internal data and tools, and continued researcher oversight.
Explore the original sources
Source date: 22 October 2026.
Published by AI Radar: 23 Oct 2026, 11:09 (Istanbul, UTC+3). Updated: 24 Oct 2026, 04:09.
FOLLOW THE TOPIC
Topics and tags
Share your discovery.
Send this story to a friend.
Reader comments
What do you think about this development? Share your experience or question. Comments are published after editorial approval.
Your name/nickname and comment become public if approved. Read: Privacy notice.
Loading comments…